Canada approves first generic semaglutide injection for weight loss
Advertisement
Read this article for free:
or
Already have an account? Log in here »
We need your support!
Local journalism needs your support!
As we navigate through unprecedented times, our journalists are working harder than ever to bring you the latest local updates to keep you safe and informed.
Now, more than ever, we need your support.
Starting at $15.99 plus taxes every four weeks you can access your Brandon Sun online and full access to all content as it appears on our website.
Subscribe Nowor call circulation directly at (204) 727-0527.
Your pledge helps to ensure we provide the news that matters most to your community!
To continue reading, please subscribe:
Add Brandon Sun access to your Free Press subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on brandonsun.com
- Read the Brandon Sun E-Edition, our digital replica newspaper
*Your next Free Press subscription payment will increase by $1.00 and you will be charged $20.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
OTTAWA – Health Canada has approved the first generic semaglutide injection for weight loss.
The product from the Canadian company Apotex is known as Svemia and is a generic version of the brand-name drug Wegovy from Denmark’s Novo Nordisk.
Health Canada says Svemia is for the once-weekly treatment of people 12 and over, as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.
It’s the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.
Generic versions of Novo Nordisk’s Ozempic by India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year.
Health Canada says it’s reviewing six other submissions for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months.
This report by The Canadian Press was first published June 29, 2026.